ICD indications

From Textbook of Cardiology
Revision as of 21:54, 10 March 2013 by Drj (talk | contribs)
Jump to navigation Jump to search

ICD indications

For all indications patient should be on optimal medical therapy and have a life expectancy of > 1 year.

Class I

  • Patients with left ventricular dysfunction due to prior myocardial infarction who are at least 40 days post MI with LVEF <30-40%, are NYHA class II or III and are receiving chronic optimal medical therapy and with life expectancy > 1 year. IAESCSCD
  • LV dysfunction due to prior MI, presenting with hemodynamically unstable sustained VT. IAESCSCDESCHF
  • Patients with non-ischemic dilated cardiomyopathy (NI DCM) with LV dysfunction who have sustained VT or VF. IAESCSCD
  • NI DCM LVEF<30-35%. NYHA II-III. Chronic medical therapy. Life expectancy > 1 year. IBESCSCD
  • Hypertrophic cardiomyopathy with sustained VT or VF. IBESCSCD
  • Arrhythmogenic right ventricular cardiomyopathy with documented sustained VT or VF. OMT, LE>1y.IB ESCSCD
  • Sustained VT, hemodynamically unstable VT, VT with syncopy, or VF. LVEF< 40%. IAESCSCD
  • LQTS with previous cardiac arrest. IAESCSCD
  • Brugada syndrome with previous cardiac arrest. ICESCSCD
  • CPVT with previous cardiac arrest. ICESCSCD
  • An ICD is recommended in a patient with heart failure with a ventricular arrhythmia causing haemodynamic instability, who is expected to

>1 year with good functional status, to reduce the risk of sudden death. IA ESCHF

  • CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 130ms, EF<30%, NYHA II. IA ESCHF
  • CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 120ms, EF<35%, NYHA III-IV. IA ESCHF

Class IIa

  • LV dysfunction due to prior MI, at least 40 days post MI, LVEF < 30-35%, NYHA I, on chronic medical therapy, life expectancy >1y. IIaBESCSCD
  • Recurrent VT in post MI patient with normal or near normal LVEF on chronic medical therapy, life expectancy > 1y. IIaCESCSCD
  • In patients with life threatening arrhythmias who are not in the acute phase of myocarditis, on chronic medical therapy, life expectancy >1y. IIaCESCSCD
  • Unexplained syncope, significant LV dysfunction, non-ischemic DCM. Optimal medical therapy, LE>1y. IIaCESCSCD
  • Sustained VT with (near) normal LV function and non-ischemic DCM. Optimal medical therapy, LE>1y. IIaCESCSCD
  • Hypertrophic cardiomyopathy with one or more major risk factors. Optimal medical therapy, LE>1y. IIaCESCSCD
  • Arrhythmogenic right ventricular cardiomyopathy with extensive disease, including those with LV dysfunction 1 or more affected family members with SCD, or undiagnosed syncope when VT or VF has not been excluded as the cause of syncope. OMT, LE>1y.IB ESCSCD
  • CRTD, NYHA III/IV, SR, QRS>120ms. IIaB. ESCSCD
  • LQTS with syncope and / or VT while on beta blockers. ESCSCD
  • Brugada syndrome with spontaneous type I ECG and who have had syncope. ESCSCD
  • Brugada syndrome with documented VT that has not resulted in cardiac arrest. ESCSCD
  • A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<35%, NYHA III-IV . IIaAESCHF
  • A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<30%, NYHA II . IIaAESCHF
  • A CRTD/CRTP may be considered to reduce the risk of HF worsening in a patient who is pacemaker dependant, after AV nodal ablation QRS > 150ms, EF<35%, NYHA III-IV . IIaAESCHF

Class IIb

  • ICD implantation is not recommended during the acute phase of myocarditisESCSCD
  • nonischemic DCM, LVEF < 30-35%, NYHA I. optimal medical therapy, LE>1y. IIbCESCSCD


References

<biblio>

  1. ESCSCD pmid=16935866
  2. ESCHF pmid=22828712

</biblio>